PHASE

I

STATUS

Active, Recruitment Closed

Personalised Cancer Vaccine

Neoantigen mRNA vaccine

SWP1001-06

A Phase I Clinical Study to Evaluate the Tolerability, Safety, Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients with Advanced Malignant Solid Tumours

Immunotherapy combination

anti-PD-1 plus anti-CCR8

LM108-01-101

A Phase I/II, First-in-Human, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours

Immunotherapy

bispecific antibody directed against PD-L1 and CD47

BAT-7104-002-CR

A Phase I, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours

Immunotherapy combination

small molecule CD73 inhibitor plus anti-PD1

ATG-037-001 | STAMINA

A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors 

Targeted therapy combination

small molecule SHP2 inhibitor plus anti-PD-L1

GO43712

A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination with Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumours

Targeted therapy

small molecule EGFR/HER2 inhibitor

ORIC-114-01

An Open-Label, Phase 1/1b, Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Targeted therapy

mRNA +/- anti-PD-L1

mRNA-2752-P101

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade

Targeted therapy

mRNA +/- anti-PD-1

mRNA-4359-P101

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Targeted therapy combination

SHP2i plus KRAS G12Ci

NAV-1003 (ARGONAUT)

A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Immunotherapy

ROR1 BiTE

EMB07X101

A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors

Targeted therapy combination

HPKi +/- anti-PD-1 antibody

BGB-A317-15025-101

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Immunotherapy combination

anti-PD-1 + anti-LAG-3 + anti-TIM-3

INCAGN 2385-201

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Immunoconjugate

FRα antibody drug conjugate

AMT-151-01

First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Immunoconjugate combinations

IL-2 / anti-IL-2 conjugate +/- chemotherapy or ICI

SLC-3010-001

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors

Personalised Cancer Vaccine

patient-specific cancer neoepitope immunotherapy

EVX-01-001

An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination with Pembrolizumab in Checkpoint Inhibitor Treatment Naive Adults with Unresectable or Metastatic Melanoma

Targeted Adjuvant Therapy

BRAF/MEKi

COLUMBUS-AD

Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group.

Adjuvant Immunotherapy

anti-PD-1 +/- anti-TIGIT

KEYVIBE-010

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled
Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus
Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma

Immunotherapy

anti-PD-1/LAG3 bispecific antibody

BP43963

A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Targeted Therapy combination

ATR Kinase inhibitor +/- anti-PD-L1 antibody

MONETTE

A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Targeted therapy

ALK/ROS/RET targeted therapy vs immunotherapy

B042777

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer

Immunotherapy combinations

anti-PD-1 +/- novel IO +/- chemotherapy

BGB-LC-201

A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Immunoconjugate

Antibody-drug conjugate

SHR-A1904-I-104

An Open-label, Single-arm, Multi-center Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1904 in Subjects with Advanced Solid Tumours

Immunotherapy combinations

chemotherapy combination +/- anti-PD-1 +/- anti-LAG-3

BGB-A317-LBL-007-201

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer